Holen Sie sich die Stockscreener-App
2.01
9.24%
0.17
Handel nachbörslich:
2.01
Schlusskurs vom Vortag:
$1.84
Offen:
$1.81
24-Stunden-Volumen:
764.61K
Relative Volume:
0.83
Marktkapitalisierung:
$242.90M
Einnahmen:
$36.86M
Nettoeinkommen (Verlust:
$-171.67M
KGV:
-0.9853
EPS:
-2.04
Netto-Cashflow:
$-171.05M
1W Leistung:
+3.61%
1M Leistung:
-5.19%
6M Leistung:
-41.91%
1J Leistung:
+41.55%
1-Tages-Spanne:
$1.80
$2.04
1-Wochen-Bereich:
$1.80
$2.04
52-Wochen-Spanne:
$1.15
$6.2801
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Firmenname
Mersana Therapeutics Inc
Sektor
Branche
Telefon
617-498-0020
Adresse
840 MEMORIAL DRIVE, CAMBRIDGE
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-07-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-07-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-07-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-07-27 | Herabstufung | Truist | Buy → Hold |
| 2023-07-27 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-06-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-06-15 | Eingeleitet | Guggenheim | Buy |
| 2023-03-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-20 | Eingeleitet | Citigroup | Buy |
| 2022-11-21 | Eingeleitet | Truist | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-31 | Eingeleitet | Credit Suisse | Neutral |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-04-29 | Eingeleitet | BTIG Research | Buy |
| 2020-01-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-11-14 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-03-19 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Mersana Therapeutics Inc Aktie (MRSN) Neueste Nachrichten
MRSN (Mersana Therapeutics) Revenue : $29.94 Mil (TTM As of Jun. 2024) - GuruFocus.com
Mersana Therapeutics exec Bala Mohan sells stock worth $3,579 - Investing.com India
Mersana Therapeutics exec Bala Mohan sells stock worth $3,579 By Investing.com - Investing.com South Africa
SG Americas Securities LLC Reduces Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics Inc’s Market Journey: Closing Weak at 2.05, Down -2.38 - The Dwinnex
Exchange Traded Concepts LLC Acquires 41,586 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $6.00 Average Price Target from Brokerages - Defense World
SILVERARC CAPITAL MANAGEMENT, LLC Reduces Stake in Mersana Therapeutics Inc - GuruFocus.com
Investing in Mersana Therapeutics Inc (MRSN) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
Mersana Therapeutics Inc (MRSN) gets rating Upgrade from JP Morgan - Knox Daily
Market Watch Highlights: Mersana Therapeutics Inc (MRSN) Ends on an Upturn Note at 1.97 - The Dwinnex
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Mersana Therapeutics Inc [MRSN] Records 50-Day SMA of $1.6854 - Knox Daily
Get in on Mersana Therapeutics Inc’s (MRSN) buy-in window today! - SETE News
Financial Metrics Check: Mersana Therapeutics Inc (MRSN)’s Ratios for Trailing Twelve Months - The Dwinnex
Mersana Therapeutics Inc [MRSN] Investment Appeal on the Rise - Knox Daily
Can you still get a good price for Mersana Therapeutics Inc (MRSN) Shares at this point? - US Post News
MRSN: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Mersana Therapeutics exec sells over $27k in company stock - Investing.com
Mersana Therapeutics exec sells over $27k in company stock By Investing.com - Investing.com Canada
Mersana Therapeutics executive sells over $27,000 in company stock By Investing.com - Investing.com Canada
Mersana Therapeutics executive sells over $16k in stock - Investing.com
Mersana Therapeutics executive sells over $27,000 in company stock - Investing.com
Mersana Therapeutics executive sells over $27k in company stock - Investing.com
Mersana Therapeutics, Inc. (NASDAQ:MRSN) SVP Alejandra Carvajal Sells 5,598 Shares - MarketBeat
Mersana Therapeutics executive sells over $27k in stock - Investing.com
Mersana Therapeutics Inc (MRSN) can make a big difference with a little luck - SETE News
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Fly 29% But Investors Aren't Buying For Growth - Simply Wall St
Mersana Therapeutics Inc’s Banking’s 100-Day Moving Average at 1.9571: Will the Stock Break Through? - The InvestChronicle
Mersana Therapeutics Inc [MRSN] Insider Activity: An Update for Investors - Knox Daily
Renaissance Technologies LLC Raises Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Is Mersana Therapeutics Inc (MRSN) worth investing in despite its overvalued state? - US Post News
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Bought by XTX Topco Ltd - Defense World
A Look at Mersana Therapeutics Inc (MRSN) Shares in the Recent Past Indicates Growth - SETE News
Affinity Asset Advisors LLC Sells 233,000 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
How Analyst Ratings Affect Mersana Therapeutics Inc Inc. (MRSN) Price Performance - The InvestChronicle
Federated Hermes Inc. Acquires 185,331 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Head-To-Head Review: KalVista Pharmaceuticals (NASDAQ:KALV) vs. Mersana Therapeutics (NASDAQ:MRSN) - Defense World
Mersana Therapeutics Inc (MRSN) stock analysis: A comprehensive overview - US Post News
Daily Progress: Mersana Therapeutics Inc (MRSN) Drop -1.37, Closing at 2.16 - The Dwinnex
Bank of New York Mellon Corp Grows Stock Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Sold by Acadian Asset Management LLC - Defense World
Acadian Asset Management LLC Has $143,000 Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
StockNews.com Lowers Mercury Systems (NASDAQ:MRCY) to Sell - Defense World
Mereo BioPharmaLazarus-Like Recovery Impresses, But Lack Of Clarity On Potential Approval Timelines - Seeking Alpha
Mersana Therapeutics Inc’s latest rating changes from various analysts - Knox Daily
There is no doubt that Mersana Therapeutics Inc (MRSN) ticks all the boxes. - SETE News
Mereo Biopharma Group Plc ADR (MREO) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Quest Partners LLC Raises Position in Mercury Systems, Inc. (NASDAQ:MRCY) - Defense World
Finanzdaten der Mersana Therapeutics Inc-Aktie (MRSN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):